Thrombolytic Therapy With Tissue Plasminogen Activator or Streptokinase Induces Transient Thrombin Activity

We have determined the plasma level of fibrinopeptide A as a specific index of thrombin activity during the infusion of a thrombolytic agent in patients with acute myocardial infarction. Peripheral venous plasma levels of fibrinopeptide A increased following the initiation of thrombolytic therapy fr...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 72; no. 2; pp. 616 - 620
Main Authors Owen, John, Friedman, Kenneth D., Grossman, Betty A., Wilkins, Carol, Berke, Andrew D., Powers, Eric R.
Format Journal Article
LanguageEnglish
Published Washington, DC Elsevier Inc 01.08.1988
The Americain Society of Hematology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We have determined the plasma level of fibrinopeptide A as a specific index of thrombin activity during the infusion of a thrombolytic agent in patients with acute myocardial infarction. Peripheral venous plasma levels of fibrinopeptide A increased following the initiation of thrombolytic therapy from 2.7 nmol/L to a peak of 13.0 nmol/L at 30 minutes with streptokinase and from 1.1 nmol/L to a peak of 10.7 nmol/L at 90 minutes with tissue plasminogen activator. The amount of fibrinogen converted to fibrin I was determined by integration of the plasma level of fibrinopeptide A over time. The amount of fibrin I formed over the five-hour period from the start of drug infusion was approximately 10 mg/dL in response to either streptokinase or recombinant tissue plasminogen activator. We conclude that activation of coagulation occurs in response to thrombolytic therapy despite heparin administration. This thrombin action, though transient, would be sufficient to cause rethrombosis if localized and incompletely opposed by fibrinolytic activity. © 1988 by Grune & Stratton, Inc.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V72.2.616.616